Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

Notable Labs119 enrolled

Overview

This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.

This is a prospective, multicenter, observational study with collection of de-identified biospecimens with matched clinical data from up to 1000 participants from clinical networks in the United States and Canada. Clinical information, demographics, and medical data relevant to cancer status are collected from all participants and their medical record at baseline (at study entry and time of baseline biospecimen collection), and subsequent visits per patient consent, for up to 1 year. The primary assessment is the establishment of a tumor registry with annotated clinical outcomes. Exploratory assessments include correlation of ex vivo functional testing results with clinical outcomes, as well as identification of potential biomarkers that correlate responses with genotype and/or phenotype.

Study Type

OBSERVATIONAL

Enrollment

119

Conditions

Acute Myelogenous Leukemia Multiple Myeloma Myelodysplastic Syndromes Lymphoma Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia Myeloproliferative Neoplasm

Interventions

This is a non-interventional studyOTHER

N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provide written informed consent; * Age ≥ 18 years, male or female, of any race; * Documented hematologic malignancy (any of the below) in need of starting an active anti-cancer therapy: * Acute myelogenous leukemia (AML) * Multiple myeloma (MM) * Myelodysplastic syndrome (MDS) * Lymphoma * Acute lymphocytic leukemia (ALL) * Chronic lymphocytic leukemia (CLL) * Chronic myelogenous leukemia (CML) * Neoplasm (MPN) * Other (upon review and approval by medical monitor) Note: \*Supportive care agents including erythropoiesis-stimulating agents (ESAs) such as EPO, Procrit, Aranesp, etc; granulocyte colony stimulating factor (G-CSF); hydroxyurea (Hydrea); and luspatercept (Reblozyl) are not considered anti-cancer therapy for this study * Intent to start anti-cancer therapy within 21 days of biospecimen collection •≥7 days from last anti-cancer therapy; * Any number of prior therapies * Subject cohort is currently open Exclusion Criteria: * Unwilling or unable to give consent * Subject's disease is in remission * Subject cohort is not open at time of consent * Subject is restarting an ongoing treatment regimen after a dose interruption

Locations (20)

CBCC Global Research

Bakersfield, California, United States

Outcomes

Primary Outcomes

Clinical response to treatment

Collect clinical responses to treatment and outcomes in patients who have provided samples to the biobank

Time frame: 3 years

Secondary Outcomes

Type of clinical treatment responses

Correlate ex vivo drug sensitivity data on patient samples with clinical treatment responses.

Time frame: 3 years

Types of somatic tumor mutations

Determine genotype and/or phenotype relationships between ex vivo and clinical responses with somatic tumor mutations.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.